liu.seSök publikationer i DiVA
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era
Umeå University, Sweden.
Karolinska University Hospital, Sweden; Karolinska Institute, Sweden.
University of Uppsala Hospital, Sweden; University of Uppsala Hospital, Sweden.
Regional Cancer Centre, Sweden.
Visa övriga samt affilieringar
2015 (Engelska)Ingår i: British Journal of Haematology, ISSN 0007-1048, E-ISSN 1365-2141, Vol. 169, nr 5, s. 683-688Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Given that tyrosine kinase inhibitors (TKIs) have dramatically improved the survival of patients with chronic myeloid leukaemia (CML), we were interested in examining the possible risk of long-term adverse events, such as the emergence of other neoplasms. Therefore, we studied the development of second malignancies in 868 patients diagnosed with CML between 2002 and 2011 using the Swedish CML register, cross-linked to the Swedish Cancer register. With a median follow-up of 37 (range 0-99)years, 65 (75%) patients developed 75 second malignancies (non-haematological), 52 of which were of the invasive type. Compared to expected rates in the background population, the risk of second malignancies was higher in the CML cohort, with a standardized incidence ratio (SIR) of 152 (95% CI 113-199). The SIR before and after the second year following diagnosis of CML was 158 and 147, respectively. Among specific cancer types, gastrointestinal and nose and throat cancer were significantly increased. Founded on a population-based material, our results indicate that CML patients treated in the TKI era are at an increased risk of developing a second malignancy, with indications that this risk may more likely be linked to CML itself rather than to the TKI treatment.

Ort, förlag, år, upplaga, sidor
Wiley , 2015. Vol. 169, nr 5, s. 683-688
Nyckelord [en]
chronic myeloid leukaemia; treatment; malignancy
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
URN: urn:nbn:se:liu:diva-119236DOI: 10.1111/bjh.13346ISI: 000354489800009PubMedID: 25817799OAI: oai:DiVA.org:liu-119236DiVA, id: diva2:821266
Anmärkning

Funding Agencies|Emil Andersson Research Fund

Tillgänglig från: 2015-06-15 Skapad: 2015-06-12 Senast uppdaterad: 2017-12-04

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Personposter BETA

Dreimane, Arta

Sök vidare i DiVA

Av författaren/redaktören
Dreimane, Arta
Av organisationen
Hematologiska kliniken USInstitutionen för medicin och hälsaMedicinska fakulteten
I samma tidskrift
British Journal of Haematology
Cancer och onkologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 107 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf